Skip to main content

Table 3 Late-stage anti-amyloid agents: phase 3 dosing regimens and pharmacokinetic profiles

From: Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Agent Dose per visit and total dose* Route of administration, frequency, and dosing facility Plasma half-life Brain penetration Time to peak brain steady state exposure**
Aducanumab
Biogen
10 mg/kg IV
600–750 mg per month
IV infusion, monthly
Titration over 6 months
Infusion center
21 days < 1.5% ~ 5 months
Gantenerumab
Roche
1200 mg SC
1200 mg per month
SC injection, monthly
Titration over
6 to 10 months
Clinic
22 days ~ 1% ~ 5 months
BAN2401
Eisai
10 mg/kg IV
1200–1500 mg per month
IV infusion,
twice per month
No titration
Infusion center
5.3 days ~ 0.5% ~ 2.5 months
ALZ-801
Alzheon
265 mg orally
530 mg daily
Oral tablet, twice daily
Titration over
2 weeks
Home
36 h ~ 40% ~ 1 week
  1. Abbreviations: IV intravenous, SC subcutaneous
  2. Data sources: [11, 14, 30, 34]
  3. *Assumes adult average weight of 60–75 kg; **time to peak brain steady state concentration (without titration) = 5 times plasma t1/2 or 5 times dosing frequency, if dosing interval is longer than plasma t1/2